

# **The Extreme of “No One Left Behind”: Undiagnosed Patients**

**Rare Disease Day at the United Nations**

***New York City, February 21, 2019***

***William A. Gahl, MD, PhD***

**Senior Investigator, NHGRI**

**Director, NIH Undiagnosed Diseases Program**

# UDP

(May 19, 2008)

- **Goals:**
  - **To assist patients with unknown disorders reach an accurate diagnosis**
  - **To discover new diseases that provide insight into human physiology and genetics**

# **Intramural UDP Operations**

- Applicants submit medical records**
- Referring physician sends summary letter**
- UDP Director triages submitted records**
- Intramural NIH consultants review records**
- UDP Director makes final disposition**
- Patients/physicians receive a standard letter; advice conferred in ~25% of cases**
- If accepted, 1-week inpatient CC admission**

# UDP Numbers (2008-2019)

- **Medical Records:** >4000
- **Admitted & Evaluated:** >1200
- **Children:** ~40%
- **Neurological:** ~50%
- **Some diagnosis:** ~30%
- **Publications** 180

# 65 Year-old Man with Recurrent Meningitis


- **Age 59 - First episode of meningitis; followed by autoimmune sensorineural hearing loss**
- **Acute: Headache, unsteady gait**
- **Chronic: Uses wheelchair, memory decline**
- **Age 59-65 – 27 more episodes**
- **LPs: Lymphocytic pleiocytosis**
- **Aseptic; steroid responsive**
- **Negative imaging; negative rheumatology evaluation**
- **Normal labs, including CRP, ESR**
- **No diagnosis at Emory, Cleveland Clinic, Mayo (Fl), Hopkins**

# 65 Year-old Man with Recurrent Meningitis



- **Exomes: Thr915Met in NLRP3**
- **NLRP3: Familial cold autoinflammatory syndrome or Muckle-Wells syndrome**
- **Heterozygous; gain of function**

- **NLRP3 is part of the Inflammasome.**
- **A gain of function mutation will increase IL-1 activity.**



- **We treated with the IL-1 receptor inhibitor, anakinra**
- **In 4 hours, he walked and talked normally**

# Diagnoses



# Very Very Rare Diagnoses

- Congenital Disorder of Glycosylation type 2b (2<sup>nd</sup> and 3<sup>rd</sup> cases in world)
- Adducted Thumb-Clubfoot Syndrome & *CHST14* mutations (1<sup>st</sup> case in U.S.)
- Spinocerebellar ataxia, myoclonic epilepsy & *AFG3L2* muts (1<sup>st</sup> AR case)
- Autosomal Dominant Leukodystrophy & *LMNB1* duplication (~10 in world)
- Adenylosuccinate lyase def. (~60 cases)
- Hereditary Muscular Neuropathy type 6 due to *IGHMBP2* muts (oldest pt. known)
- Fatty acid 2-hydroxylase def. (~50 cases)

# More Diagnoses

- EMARRD (Early myopathy, AReflexia, Respiratory distress, Dysphagia) due to *MEGF10* mutations
- Neurodegeneration due to *BTK* mutation
- Cognitive & motor decline with *C19orf12* muts
- Waardenburg type 2 due to *SOX10* deletion
- SLE with cerebellar ataxia and anti-GWB Abs
- GM2 gangliosidosis and Sanfilippo disease
- TEMPI syndrome with erythrocytosis muts
- Choreo-acanthocytosis due to *VPS13A*
- Aicardi-Goutieres due to *RNASEH2B*, A muts
- SPG11, NPC1, STIM1, GARS, A-T, NGLY1, MNGIE, CAV3


**Expansion**

# The Undiagnosed Diseases Network (UDN)

- UDP, 7 (now 12) Clinical Sites, Coordinating Center, 2 Sequencing Cores, Metabolomics Core, Model Organisms Screening Center, Central Repository
- Formal data sharing agreements
- Consent: PII to be shared within UDN, de-identified data with others.
- First patients: August 2015.

# Worldwide Access: UDNI

**Undiagnosed Diseases Network International(UDNI):  
White Paper for Global Actions to Meet Patient Needs**  
*Molecular Genetics and Metabolism 116:223-5, 2015.*



Undiagnosed  
Diseases Network  
**INTERNATIONAL**

**Website:**

**<http://www.udninternational.org/>**

# UDNI Meetings

(NIH Common Fund, Wilhelm Foundation, Local Sponsors)

- Rome September 2014
- Budapest – June 2015
- Vienna – February 2016
- Tokyo – November 2016
- Stockholm – August 2017
- Naples – June 2018
- Delhi – April 2019

# Undiagnosed Diseases Programs

- W. Australia

- Japan

- Austria

- Spain

- Sweden

- India

- Turkey

- Canada

- Hong Kong

- China

- Korea

- France

- Thailand

- Italy

# **CONCLUSIONS: Rare and Undiagnosed Diseases Programs**

- **Require strong phenotyping of patients**
- **Foster new disease discovery**
- **Lead to insights into common diseases**
- **Help desperate patients**
- **Often require functional studies**
- **Sometimes do not need NGS**
- **Hugely benefit from data sharing**
- **Have captured the interest of industry**
- **Are needed throughout the world**



